- Home
- TYRA vs JFR Comparison
TYRA vs JFR Comparison
Compare TYRA & JFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- JFR
- Stock Information
- Founded
- TYRA 2018
- JFR 2004
- Country
- TYRA United States
- JFR United States
- Employees
- TYRA N/A
- JFR N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- JFR Trusts Except Educational Religious and Charitable
- Sector
- TYRA Health Care
- JFR Finance
- Exchange
- TYRA Nasdaq
- JFR Nasdaq
- Market Cap
- TYRA 812.7M
- JFR 1.2B
- IPO Year
- TYRA 2021
- JFR N/A
- Fundamental
- Price
- TYRA $14.43
- JFR $8.98
- Analyst Decision
- TYRA Strong Buy
- JFR
- Analyst Count
- TYRA 5
- JFR 0
- Target Price
- TYRA $31.00
- JFR N/A
- AVG Volume (30 Days)
- TYRA 201.5K
- JFR 621.7K
- Earning Date
- TYRA 11-07-2024
- JFR 01-01-0001
- Dividend Yield
- TYRA N/A
- JFR 11.31%
- EPS Growth
- TYRA N/A
- JFR N/A
- EPS
- TYRA N/A
- JFR N/A
- Revenue
- TYRA N/A
- JFR N/A
- Revenue This Year
- TYRA N/A
- JFR N/A
- Revenue Next Year
- TYRA N/A
- JFR N/A
- P/E Ratio
- TYRA N/A
- JFR N/A
- Revenue Growth
- TYRA N/A
- JFR N/A
- 52 Week Low
- TYRA $11.24
- JFR $7.61
- 52 Week High
- TYRA $29.60
- JFR $8.82
- Technical
- Relative Strength Index (RSI)
- TYRA 42.39
- JFR 49.44
- Support Level
- TYRA $13.27
- JFR $8.89
- Resistance Level
- TYRA $14.77
- JFR $9.08
- Average True Range (ATR)
- TYRA 0.75
- JFR 0.12
- MACD
- TYRA 0.07
- JFR -0.01
- Stochastic Oscillator
- TYRA 50.19
- JFR 50.00
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.